Sensei Biotherapeutics (NASDAQ:SNSE) Receives Buy Rating from HC Wainwright

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $4.00 target price on the stock.

Sensei Biotherapeutics Price Performance

SNSE stock opened at $0.51 on Friday. The firm has a market cap of $12.78 million, a PE ratio of -0.43 and a beta of 0.16. Sensei Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.94. The firm has a 50 day simple moving average of $0.47 and a 200 day simple moving average of $0.49.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27). As a group, sell-side analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI boosted its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the quarter. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.